Bolt Biotherapeutics (BOLT) AI Stock Analysis

• Market Cap: $13.62M
• Dividend Yield: N/A
• Average Volume (3M): 145.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.74
• Revenue Growth: -2.36%
• EPS Growth: 9.68%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -1.65
• Shares Outstanding: 38,339,700
• 10 Day Avg. Volume: 126,915
• 30 Day Avg. Volume: 145,988
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.18
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -0.31
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.13
• Price Target Upside: 222.86% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4

Bolt Biotherapeutics faces significant challenges with profitability and cash flow, despite showing some revenue growth. The technical analysis indicates a bearish trend with limited upward momentum. Valuation metrics further highlight the financial difficulties, with a negative P/E ratio and no dividends. Strategic improvements in operational efficiency and financial management are crucial for enhancing stock performance.

Positive Factors

Clinical Development

BDC-3042 has been overall well tolerated with no dose-limiting toxicities and evidence of activity.

Financial Stability

Management anticipates cash runway through mid-2026.

Preclinical Performance

BDC-4182 displayed superior efficacy compared to cytotoxic claudin 18.2 ADCs in syngeneic models.

Negative Factors

Clinical Trials

The stock is expected to remain pressured until Bolt generates more meaningful clinical momentum with BDC-4182 or out-licenses BDC-3042 on favorable economic terms.

Financial Performance

Bolt reported 4Q24 revenue of $0.0M and EPS of ($0.42), compared to estimates of $0.9M and ($0.34), respectively.

Pipeline Uncertainty

Analyst maintains a Neutral rating and has no price target as more clarity on the company’s pipeline is awaited.

Bolt Biotherapeutics Business Overview & Revenue Model

Company Description

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

How the Company Makes Money

Bolt Biotherapeutics makes money primarily through the development and commercialization of its proprietary cancer therapies. The company's revenue model includes potential milestone payments and royalties from licensing agreements and partnerships with larger pharmaceutical companies. These collaborations help in the advancement of its drug candidates through clinical trials and regulatory approval processes. Additionally, Bolt may secure funding through equity offerings, grants, or government contracts to support its research and development activities. The company's earnings are influenced by the successful progression and commercialization of its drug pipeline.

Bolt Biotherapeutics Financial Statement Overview

Summary

Bolt Biotherapeutics is navigating through losses with some signs of revenue growth, but profitability remains a significant challenge. The company's balance sheet presents a low debt burden and a stable equity position, yet it struggles with cash flow inefficiencies. Continued focus on improving operational efficiencies and strategic financial management is essential to enhance overall financial health.

Income Statement

Bolt Biotherapeutics shows a modest revenue growth with a 34.3% increase from 2022 to 2023 and a slight decline of 2.4% from 2023 to 2024. However, the company has been experiencing significant losses with a negative net profit margin of -820.7% in 2024. The gross profit margin is stable at 100% for 2024, indicating that cost of goods sold is negligible compared to revenue, but high operational expenses continue to weigh down profitability.

Balance Sheet

The company maintains a relatively low debt-to-equity ratio of 0.44 in 2024, suggesting a conservative leverage approach. However, return on equity remains negative due to consistent losses, indicating inefficiencies in generating returns for shareholders. The equity ratio stands at 57.4%, reflecting a stable financial structure with more than half of its assets funded by equity.

Cash Flow

Operating cash flow remains negative, but improved slightly from -69.5 million in 2023 to -61.3 million in 2024. Free cash flow also increased marginally to -61.3 million, indicating ongoing challenges in cash generation. The operating cash flow to net income ratio of 0.97 suggests that cash flow is closely aligned with net losses, while free cash flow to net income ratio mirrors this trend.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
7.69M	7.88M	5.73M	1.26M	231.00K
	Gross Profit
7.69M	5.99M	838.00K	-2.41M	-40.13M
	EBIT
-73.05M	-76.20M	-90.32M	-92.79M	-49.18M
	EBITDA
-66.45M	-74.34M	-88.66M	-91.59M	-48.57M
	Net Income Common Stockholders
-63.12M	-69.20M	-85.88M	-104.39M	-72.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
47.32M	102.19M	168.89M	186.22M	22.84M
	Total Assets
99.63M	159.78M	227.81M	307.72M	46.54M
	Total Debt
25.21M	20.22M	22.61M	24.36M	10.88M
	Net Debt
18.00M	9.41M	13.37M	-3.03M	5.33M
	Total Liabilities
42.43M	47.04M	56.30M	57.60M	151.49M
	Stockholders Equity
57.20M	112.74M	171.51M	250.12M	-104.95M
Cash Flow		Free Cash Flow
-61.33M	-69.73M	-78.46M	-59.40M	-50.57M
	Operating Cash Flow
-61.29M	-69.53M	-76.50M	-57.07M	-47.31M
	Investing Cash Flow
57.58M	71.04M	57.86M	-232.20M	-20.59M
	Financing Cash Flow
108.00K	253.00K	503.00K	311.11M	39.60M

Bolt Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BOLT, the sentiment is Negative. The current price of 0.35 is below the 20-day moving average (MA) of 0.36, below the 50-day MA of 0.41, and below the 200-day MA of 0.56, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 46.41 is Neutral, neither overbought nor oversold. The STOCH value of 37.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BOLT.

Bolt Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.38B	3.59	-41.63%	2.87%	17.72%	1.87%
BRTX	51 Neutral	$13.21M	―	-96.89%	―	175.03%	55.34%
BOLT	44 Neutral	$13.62M	―	-74.28%	―	-2.36%	9.68%
CRIS	41 Neutral	$19.46M	―	-634.71%	―	8.83%	22.06%
MEIP	41 Neutral	$13.59M	―	-93.69%	―	-100.00%	-292.59%
CLRB	34 Underperform	$11.59M	―	-4693.38%	―	―	56.38%
INAB	34 Underperform	$13.73M	―	-154.44%	―	―	38.53%

Bolt Biotherapeutics Corporate Events

Bolt Biotherapeutics Announces Board Changes and Appointments

Dr. Mahendra Shah resigned from Bolt Biotherapeutics’ Board of Directors, effective December 31, 2024, for personal reasons. Following his resignation, Dr. Jakob Dupont was appointed to the Audit Committee and the Nominating and Corporate Governance Committee, ensuring continuity in the company’s governance.